WisdomTree U.S. SmallCap Dividend Fund Experiences Big Outflow
Written by Emily J. Thompson, Senior Investment Analyst
Source: NASDAQ.COM
Stock Performance Overview: DES's current share price is $34.31, situated between its 52-week low of $30 and high of $38.10, with technical analysis suggesting the relevance of comparing it to the 200-day moving average.
ETFs Trading Dynamics: Exchange traded funds (ETFs) function similarly to stocks, allowing for the buying and selling of units, which can be created or destroyed based on investor demand, impacting the underlying holdings significantly during notable inflows or outflows.
Analyst Views on OGN
Wall Street analysts forecast OGN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for OGN is 8.50 USD with a low forecast of 5.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
0 Buy
1 Hold
4 Sell
Strong Sell
Current: 9.590
Low
5.00
Averages
8.50
High
12.00
Current: 9.590
Low
5.00
Averages
8.50
High
12.00
About OGN
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
